Regular use of common cholesterol-lowering drug linked to reduction of COVID-19 severity, risk of death
NEW ORLEANS - Commonly used cholesterol-lowering statins may reduce the risk of death and severity of COVID-19 disease, suggests a study of more than 38,000 patients being presented at the...
“This research illustrates the importance of evaluating medications that could be repurposed to help patients in ways other than their intended use,” said Dr. Crimi. “Our results suggest statins could be an additional cost-effective solution against COVID-19 disease severity and should be studied further.”
Meaning: The results of this study suggest that ambulatory patients with COVID-19, either vaccinated or not, present a clinically relevant increased risk of incident VTE during the acute phase, with the risk pronounced by factors of older age, male sex, obesity, incomplete vaccination, and factor V Leiden thrombophilia.
Neurogenesis is disrupted in human hippocampal progenitor cells upon exposure to serum samples from hospitalized COVID-19 patients with neurological symptoms - Molecular Psychiatry
Source : https://www.nature.com/articles/s41380-022-01741-1
Coronavirus disease 2019 (COVID-19), represents an enormous new threat to our healthcare system and particularly to the health of older adults. Although the respiratory symptoms of COVID-19 are well recognized,...
Overall, our results show that serum from COVID-19 patients with delirium can negatively affect hippocampal-dependent neurogenic processes, and that this effect is mediated by IL6-induced production of the downstream inflammatory cytokines IL12 and IL13, which are ultimately responsible for the detrimental cellular outcomes.
Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525042/
Monitoring Editor: Alexander Muacevic and John R Adler Background We have previously demonstrated that ivermectin used as prophylaxis for coronavirus disease 2019 (COVID-19), irrespective of the regularity, in a strictly...
Conclusion: Non-use of ivermectin was associated with a 12.5-fold increase in mortality rate and a seven-fold increased risk of dying from COVID-19 compared to the regular use of ivermectin. This dose-response efficacy reinforces the prophylactic effects of ivermectin against COVID-19.
Meaning: This study found that the humoral response after the third vaccine dose was sustained for 5 months and that antibody kinetics were associated with Omicron infection.